The medical community is slow to adopt advanced preventative tools like genomic sequencing. Change will not come from the top down. Instead, educated and savvy patients demanding these tests from their doctors will be the primary drivers of the necessary revolution in personalized healthcare.

To overcome resistance, AI in healthcare must be positioned as a tool that enhances, not replaces, the physician. The system provides a data-driven playbook of treatment options, but the final, nuanced decision rightfully remains with the doctor, fostering trust and adoption.

Testing for hundreds of biomarkers is not inherently better and can be harmful. With a ~95% accuracy rate per test, running more tests increases the odds of a false positive. This leads to chasing down non-existent issues with doctors, initiating diagnostic processes that carry their own risks.

Constant messaging about diet and lifestyle as cancer causes fosters patient guilt. A more effective public health approach would de-emphasize these inconclusive factors and instead invest in predictive AI models that assess individual risk based on concrete factors like breast density.

While wearables generate vast amounts of health data, the medical system lacks the evidence to interpret these signals accurately for healthy individuals. This creates a risk of false positives ('incidentalomas'), causing unnecessary anxiety and hindering adoption of proactive health tech.

MedTech's data-driven culture fosters a false belief that strong clinical data is sufficient to drive adoption. In reality, all humans—including surgeons—make decisions emotionally first. Data's primary role is not to create initial belief but to provide rational validation for a change the market has already been primed to make.

The healthcare system is fundamentally reactive, designed to intervene after a failure like a disease or injury. It overlooks the gradual decline in functional capability that precedes these events, creating a massive blind spot in preventive health for the general population.

The primary barrier to successful AI implementation in pharma isn't technical; it's cultural. Scientists' inherent skepticism and resistance to new workflows lead to brilliant AI tools going unused. Overcoming this requires building 'informed trust' and effective change management.

Cancer screening is moving beyond broad demographic guidelines (e.g., age) to a model based on individual risk. This includes not only genetics and environmental exposures but also novel, passive data streams from smart devices like toilet sensors monitoring stool or even subtle changes in a person's typing patterns over time.